Brazil – Peptide Import & Customs Guide
ANVISA regulations, RDC 172/2017, labeling requirements, and customs broker tips for research peptides
High-Risk Destination
Brazil enforces strict documentation requirements under ANVISA oversight. Customs success rate is approximately 60%. Working with a local Brazilian customs broker is strongly recommended.
1. Regulatory Framework
In Brazil, the regulatory process for medicinal products is structured as a life cycle-based system governed primarily by ANVISA (Agência Nacional de Vigilância Sanitária) through a detailed framework of Resolutions of the Board of Directors (RDCs). Any product subject to ANVISA oversight must be approved before entering the Brazilian market, whether through registration, notification, authorization, or other regulatory clearance.
2. Import Requirements
Brazil's customs regulations impose strict documentation requirements. Essential documents include:
- Certifications (including Certificates of Analysis / COA)
- Commercial invoices
- Labeling that meets local standards
All regulated products must comply with Brazil's labeling rules when placed on the market. Labels must be in Brazilian Portuguese and meet specific formatting guidelines.
For products intended for scientific or technological research, imports must follow the provisions of RDC No. 172/2017.
3. Recent Regulatory Updates
On August 25, 2025, ANVISA set new rules for the importation of liraglutide, semaglutide, and tirzepatide for compounding purposes. Importers should stay informed about evolving ANVISA regulations affecting specific peptide classes.
4. Customs Clearance
5. Compliance Recommendations
Shipping to Brazil?
We recommend working with a local customs broker and preparing ANVISA-compliant documentation.